Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Long-term efficacy and safety of intravenous iron in HF

3' education - Nov. 21, 2022 - Paul R. Kalra

Applying GDMT for iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Piotr Ponikowski, MD, PhD, Adrian F. Hernandez, MD, Prof. Andrew Sindone, MD

Maximally tolerated or suboptimal therapy? Clinical perspectives on rechallenging RAASi therapy

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD & Prof. Patrick Rossignol, MD, PhD

Identifying and treating iron deficiency in heart failure

10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

Why ischemia matters when it comes to iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Marco Metra, MD & Prof. Piotr Ponikowski, MD, PhD

The role of potassium binders in optimal HF management: Discussing the DIAMOND study

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD, Prof. Stefan D. Anker, MD, PhD, Prof. Javed Butler, MD, Prof. Bertram Pitt, MD

New perspectives in managing heart failure and hyperkalemia – The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD

Improved outcomes with rapid uptitration of HF medication after acute HF

3' education - Nov. 8, 2022 - Prof. Alexandre Mebazaa, MD, PhD

Head-to-head comparison of two loop diuretics in patients hospitalized with HF

3' education - Nov. 7, 2022 - Robert J. Mentz, MD

Identification and management of patients with HFpEF and diabetes

10' education - Oct. 26, 2022 - Prof. Silvio Inzucchi, MD & Prof. Pardeep Jhund, MD, PhD

HFpEF and diabetes: What are the clinical challenges?

10' education - Oct. 25, 2022 - Prof. Pardeep Jhund, MD, PhD

SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia

10' education - Oct. 24, 2022 - Prof. Silvio Inzucchi, MD

Practical guidance on use of potassium binders in the management of hyperkalemia in heart failure

10' education - Oct. 12, 2022 - Clara Bonanad Lozano, MD, PhD

How potassium binders can enable RAASi therapy in heart failure

10' education - Oct. 11, 2022 - Prof. Mikhail Kosiborod, MD

Understanding the effects of ARNI in acute MI

3' education - Sep. 15, 2022 - Otavio Berwanger, MD, PhD

SGLT2i improves outcomes in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Combination therapy with loop diuretic and acetazolamide improves decongestion in acute HF

3' education - Aug. 27, 2022 - Prof. Wilfried Mullens, MD, PhD

Totality of evidence of SGLT2 inhibition in HF

3' education - Aug. 27, 2022 - Muthiah Vaduganathan, MD

All patients with HF regardless of EF benefit from SGLT2i

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

Prediction of life expectancy and life years gained by medication in HFrEF

3' education - Aug. 27, 2022 - Stefan Koudstaal, MD, PhD

Cognitive function not affected by ARNI

3' education - Aug. 26, 2022 - Prof. John McMurray, MD

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022

Expanding evidence on SGLT2i: Where are we now and what can we expect?

10' education - July 21, 2022 - Prof. Scott Solomon, MD

Discussion - Clinical dilemmas in heart failure: Weighing the balance of RAASi and hyperkalaemia

10' education - July 20, 2022 - Prof. Andrew Coats, MD, Clara Bonanad Lozano, MD, PhD, and Aaron Wong, MD

Potassium binding as RAASi enabling therapy: applying recent insights into practice

10' education - July 18, 2022 - Aaron Wong, MD

New perspectives on the management of HFrEF: iron deficiency and cardiac remodeling

10' education - July 12, 2022 - Prof. Peter van der Meer, MD, PhD and Pieter Martens, MD, PhD

Hyperkalemia in heart failure: Why should we care?

10' education - July 12, 2022 - Clara Bonanad Lozano, MD, PhD

Optimizing RAASi therapy: The role of personalized therapy

10' education - July 5, 2022 - Prof. George Bakris, MD and prof. Giuseppe Rosano, MD, PhD

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD

Low adherence and persistence with HF therapies in new-onset HF

Literature - Nov. 29, 2022 - Ødegaard KM, et al. - ESC Heart Fail. 2022

A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

SGLT2 inhibition leads to early decongestion and clinical benefit in acute HF

Literature - Nov. 22, 2022 - Biegus J, et al. - Eur Heart J. 2022

In 530 patients hospitalized for acute HF, empagliflozin treatment resulted in early, clinically meaningful decongestion compared with placebo. The magnitude of decongestion was associated with clinical benefit at day 90.

Long-term efficacy and safety of intravenous iron in HF

3' education - Nov. 21, 2022 - Paul R. Kalra
Paul Kalra shares the results of the IRONMAN study that investigated the effects of ferric derisomaltose on cardiovascular events in patients with iron deficiency and HF.

AHA 2022 Paul Kalra shares the results of the IRONMAN study that investigated the effects of ferric derisomaltose on cardiovascular events in patients with iron deficiency and HF.

Applying GDMT for iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Piotr Ponikowski, MD, PhD, Adrian F. Hernandez, MD, Prof. Andrew Sindone, MD
Three experts talk about strategies on applying guideline-directed medical therapy to patients with heart failure and iron deficiency: the who, why, and how.

Three experts talk about strategies on applying guideline-directed medical therapy to patients with heart failure and iron deficiency: the who, why, and how.

Maximally tolerated or suboptimal therapy? Clinical perspectives on rechallenging RAASi therapy

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD & Prof. Patrick Rossignol, MD, PhD
In HF, the use of MRAs is often delayed despite being a crucial part of medical therapy. Prof. Ileana Piña and Prof. Patrick Rossignol discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for patients with HF.

In HF, the use of MRAs is often delayed despite being a crucial part of medical therapy. Prof. Ileana Piña and Prof. Patrick Rossignol discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for patients with HF.

Identifying and treating iron deficiency in heart failure

10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD
Robert Mentz and Peter van der Meer discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.

Robert Mentz and Peter van der Meer discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD
Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

Why ischemia matters when it comes to iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Marco Metra, MD & Prof. Piotr Ponikowski, MD, PhD
Prof. Metra and Prof. Ponikowski talk about the significance of ischemic etiology and iron deficiency in the management of patients with heart failure.

Prof. Metra and Prof. Ponikowski talk about the significance of ischemic etiology and iron deficiency in the management of patients with heart failure.

The role of potassium binders in optimal HF management: Discussing the DIAMOND study

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD, Prof. Stefan D. Anker, MD, PhD, Prof. Javed Butler, MD, Prof. Bertram Pitt, MD
Four experts discuss the value of the results from the DIAMOND trial and the body of clinical evidence for use of potassium binders in the management of hyperkalemia in patients with heart failure.

Four experts discuss the value of the results from the DIAMOND trial and the body of clinical evidence for use of potassium binders in the management of hyperkalemia in patients with heart failure.

New perspectives in managing heart failure and hyperkalemia – The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD
RAASi therapy is a critical component of HF management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. Prof. Kosiborod and Prof Stack discuss how to manage hyperkalemia while continuing to up-titrate RAASi therapy in patients with HFrEF & CKD.

RAASi therapy is a critical component of HF management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. Prof. Kosiborod and Prof Stack discuss how to manage hyperkalemia while continuing to up-titrate RAASi therapy in patients with HFrEF & CKD.

Limited influence of ARNI on loop diuretic use in symptomatic HFpEF

Literature - Nov. 14, 2022 - Chatur S, et al. - Eur J Heart Fail. 2022

In patients with HFrEF, the use of sacubitril/valsartan may allow a reduction in loop diuretic requirement, but how does sacubitril/valsartan affect longitudinal patterns in loop diuretic use in HFpEF patients?

Improved outcomes with rapid uptitration of HF medication after acute HF

3' education - Nov. 8, 2022 - Prof. Alexandre Mebazaa, MD, PhD
Prof. Mebazaa explains why patients and healthcare providers will love the STRONG-HF regimen of quick uptitration of HF therapies in hospitalized acute HF patients ready for discharge.

AHA 2022 Prof. Mebazaa explains why patients and healthcare providers will love the STRONG-HF regimen of quick uptitration of HF therapies in hospitalized acute HF patients ready for discharge.